Patients with SMA Type 3 often experience muscle weakness that begins in the proximal muscles, particularly those of the hips, thighs, and shoulders. This weakness can lead to difficulties in walking, running, and climbing stairs. Over time, muscle atrophy, or wasting, may occur. Unlike more severe forms of SMA, individuals with Type 3 usually maintain the ability to sit and stand independently for many years. However, they may experience fatigue and muscle cramps.

Diagnosing SMA Type 3 involves a combination of clinical evaluation, family history, and genetic testing. A neurologist may perform a physical examination to assess muscle strength and reflexes. Genetic testing is crucial for confirming the diagnosis, as it can identify mutations in the SMN1 gene, which are responsible for the condition. Electromyography (EMG) and nerve conduction studies may also be conducted to evaluate the electrical activity of muscles and nerves.

While there is no cure for SMA Type 3, several treatments can help manage symptoms and improve quality of life. Physical therapy is often recommended to maintain muscle strength and flexibility. Occupational therapy can assist with daily activities. In recent years, medications such as nusinersen and risdiplam have been approved to treat SMA by increasing the production of the SMN protein, which is deficient in these patients. Supportive care, including nutritional support and respiratory management, may also be necessary.

The prognosis for individuals with SMA Type 3 varies. Many patients maintain the ability to walk into adulthood, although some may eventually require a wheelchair. Life expectancy is generally normal, but quality of life can be affected by the degree of muscle weakness and associated complications. Early intervention and ongoing management can significantly improve outcomes.

SMA Type 3 is caused by mutations in the SMN1 gene, which is responsible for producing the survival motor neuron (SMN) protein. This protein is essential for the maintenance of motor neurons, the nerve cells that control muscle movement. The condition is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to develop the disease.

SMA is a relatively rare condition, with an estimated incidence of 1 in 10,000 live births. SMA Type 3 accounts for approximately 30% of all SMA cases. The condition affects both males and females equally and is found in all ethnic groups. Carrier frequency is higher, with about 1 in 50 people being carriers of the SMN1 gene mutation.

The pathophysiology of SMA Type 3 involves the degeneration of motor neurons in the spinal cord and brainstem due to insufficient levels of the SMN protein. This degeneration leads to muscle weakness and atrophy, as the affected neurons are unable to effectively transmit signals to the muscles. The severity of symptoms correlates with the amount of functional SMN protein present, which is influenced by the number of copies of the SMN2 gene, a closely related gene that can partially compensate for the loss of SMN1 function.

Currently, there is no way to prevent SMA Type 3, as it is a genetic condition. However, genetic counseling is recommended for families with a history of SMA. Carrier testing can identify individuals who carry the SMN1 gene mutation, allowing for informed family planning decisions. Prenatal testing and preimplantation genetic diagnosis are options for at-risk couples who wish to have children.

Spinal muscular atrophies (SMAs) are neurodegenerative disorders caused by mutations in the survival motor neuron 1 (SMN1) gene. Progressive destruction of neurons located in the anterior horn of the spinal cord develops as a result of homozygous deletion of specific segments (exon 7) on SMN1 through autosomal recessive patterns of inheritance [1]. SMAs are estimated to occur in 1 every 10,000 births and type 3 (known as Kugelberg-Welander disease) comprises about 30% of all cases [1] [2]. The onset of symptoms ranges between 18 months - 30 years of age, and further classification divides type 3 into type 3a (onset between 18 months and 3 years) and 3b (onset between 3-30 years) [1]. Progressive weakness of proximal limbs, more commonly involving the legs than arms, is a typical finding that may be severe enough to require use of a wheelchair or walking aids [3]. Respiratory muscle weakness, which predisposes the majority of patients suffering from type 1 or type 2 to nocturnal hypoventilation, recurrent infections and respiratory failure, as well as swallowing difficulties and scoliosis, are usually absent in type 3 individual, and life expectancy is rarely shortened by complications of the disease [1] [3] [4]. Additional signs of SMA type 3 are joint pain and preserved cognitive skills [3]. Initial diagnostic workup should comprise serum creatine kinase (CK) levels, electromyography (EMG) and nerve conduction studies, while confirmation can be obtained by using molecular and genetic tests that will detect homozygous deletion of SMN1 [4] [5]. Treatment focuses on symptomatic measures, mainly to provide support when walking or experiencing symptoms of weakness, while more severe measures (insertion of feeding tubes or assisted ventilation) are rarely necessary, and are reserved for more severe forms of SMA (types 1 and 2) [1] [4] [5].

For patients and families affected by SMA Type 3, understanding the condition is essential. It is important to work closely with a healthcare team, including neurologists, physical therapists, and genetic counselors, to develop a comprehensive care plan. Staying informed about new treatments and participating in support groups can provide additional resources and emotional support. Regular follow-up appointments are necessary to monitor the progression of the disease and adjust treatment plans as needed.

1. Arnold WD, Kassar D, Kissel JT. Spinal Muscular Atrophy: Diagnosis and Management in a New Therapeutic Era. Muscle Nerve. 2015;51(2):157-167.
2. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens. Eur J Hum Genet. 2012;20(1):27-32.
3. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015;33(4):831-846.
4. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-1049.
5. Prior TW. Spinal muscular atrophy diagnostics. J Child Neurol. 2007;22(8):952-956.